Sun Pharmaceutical Industries will look at strategic acquisitions, including smaller “tuck-ins,” top-management said, outlining strategy, without commenting on specifics being reported in the media.
The company will look at acquisitions only if it helps strengthening long-term strategic opportunity, Dilip Shanghvi, Sun Pharma’s Executive Chairman told analysts, after it announced its financial performance for the third quarter ended December 31, 2025. The company will remain “disciplined” on acquisitions, he said, and find a way to grow organically. It would look at an acquisition “only if it helps strengthening long-term strategic opportunity,” he said, adding that they were comfortable raising debt.
The United States is important to Sun’s innovative products business, he said, adding that they were looking to sell their innovative products in other global markets as well. The company would also look at “tuck-ins”or smaller acquisitions in emerging markets, he added.
Sun Pharma has recently been reported as looking for a major acquisition in the US, that would bolster its presence in women’s health. The company, however, called the report “speculative,” in its response to the stock exchanges.
The drugmaker clocked a 16 percent growth in net profit at ₹3,368 crore, for the third quarter Q3, ended December 31, 2025. The company clocked a 15 percent growth in sales at ₹15,469 crore, for the period under review. Its global innovative medicines (specialty business) stood at $423 million, including a $55 million milestone payment. This was up 13.2 per cent accounting for 21.2 per cent of sales, ex-milestone, it said.
Kirti Ganorkar, Sun Pharma’s Managing Director said, that the company was looking to launch generic semaglutide on day one of patent expiry on the obesity and diabetes drug.
On the performance in Q3, he said, “Our results this quarter demonstrate well‑rounded growth across all businesses, prominently led by our branded businesses in India, Emerging Markets and Global Innovative Medicines. Our innovative product offering has expanded further with the launch of Unloxcyt in the US and the introduction of Ilumya in India.”
Published on January 31, 2026
